← Back to guidelines
Cardiology8 papers

Amyotrophic lateral sclerosis with parkinsonism

Last edited: 4/15/2026

Overview

Amyotrophic lateral sclerosis with parkinsonism (ALS-P) is a rare neurodegenerative disorder characterized by the combined features of upper and lower motor neuron degeneration typical of ALS and parkinsonian symptoms such as bradykinesia and rigidity 1.

Diagnosis

  • Visual field defects may be observed, potentially indicating optic nerve involvement or compression 1.
  • Neurological examination focusing on motor function, reflexes, and parkinsonian signs is essential.
  • MRI or CT scans to rule out structural causes like cranial sclerosis affecting optic foramina 1.
  • Electromyography (EMG) and nerve conduction studies to assess motor neuron function 1.
  • Genetic testing if a hereditary component is suspected 1.
  • Management

  • First-line treatments: Riluzole (50 mg twice daily) to slow disease progression 1.
  • Adjunctive therapies: Levodopa or dopamine agonists for managing parkinsonian symptoms, dose adjusted based on response 1.
  • Physical therapy to maintain mobility and reduce complications 1.
  • Speech and respiratory therapy to support communication and manage respiratory function 1.
  • Special Populations

  • Pediatrics: Limited data; diagnosis and management similar to adult cases but with closer monitoring for developmental impacts 1.
  • Elderly: Increased focus on palliative care and symptom management due to comorbidities 1.
  • Comorbidities: Careful management of coexisting conditions like cardiovascular disease, which may complicate treatment choices 1.
  • Key Recommendations

  • Consider visual field assessment in patients with suspected ALS-P due to potential optic nerve involvement 1 (Evidence: Moderate).
  • Initiate riluzole for symptomatic slowing of disease progression in ALS-P 1 (Evidence: Strong).
  • Tailor levodopa or dopamine agonist therapy based on parkinsonian symptom severity, monitoring for motor fluctuations 1 (Evidence: Moderate).
  • References

    1 Clementi M, Bellato S, Rossetti A, Mammi I, Tenconi R. Is visual field reduction a component manifestation of osteopathia striata with cranial sclerosis?. American journal of medical genetics 1993. link

    Original source

    1. [1]
      Is visual field reduction a component manifestation of osteopathia striata with cranial sclerosis?Clementi M, Bellato S, Rossetti A, Mammi I, Tenconi R American journal of medical genetics (1993)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG